Aptargroup/$ATR
1D1W1MYTD1Y5YMAX
Capital at risk
About Aptargroup
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
- Ticker
- $ATR
- Sector
- Materials
- Primary listing
- NYSE
- Employees
- 14,000
- Headquarters
- Crystal Lake, United States
- Website
- www.aptar.com
Aptargroup Metrics
BasicAdvanced
$7.9B
22.47
$5.55
0.38
$1.92
1.54%
Price and volume
Market cap
$7.9B
Beta
0.38
52-week high
$146.91
52-week low
$103.23
Average daily volume
408K
Dividend rate
$1.92
Financial strength
Current ratio
1.614
Quick ratio
0.978
Long term debt to equity
0.418
Total debt to equity
0.528
Dividend payout ratio (TTM)
33.84%
Interest coverage (TTM)
7.74%
Profitability
EBITDA (TTM)
798.655
Gross margin (TTM)
36.07%
Net profit margin (TTM)
9.22%
Operating margin (TTM)
12.49%
Effective tax rate (TTM)
20.15%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
6.14%
Return on equity (TTM)
13.46%
Valuation
Price to earnings (TTM)
22.467
Price to revenue (TTM)
2.048
Price to book
3.02
Price to tangible book (TTM)
5.09
Price to free cash flow (TTM)
26.107
Free cash flow yield (TTM)
3.83%
Free cash flow per share (TTM)
4.776
Dividend yield (TTM)
1.54%
Forward dividend yield
1.54%
Growth
Revenue change (TTM)
8.93%
Earnings per share change (TTM)
-4.15%
3-year revenue growth (CAGR)
5.09%
10-year revenue growth (CAGR)
5.35%
3-year earnings per share growth (CAGR)
13.65%
10-year earnings per share growth (CAGR)
6.06%
3-year dividend per share growth (CAGR)
7.53%
10-year dividend per share growth (CAGR)
4.82%
What the Analysts think about Aptargroup
Analyst ratings (Buy, Hold, Sell) for Aptargroup stock.
Analyst projections of the future price of Aptargroup stock.
Bulls say / Bears say
Management expects solid growth across all three segments in the third quarter and guided adjusted EPS to $1.45-$1.53; it also expects the emergency-medicine destocking headwind to abate by the fourth quarter. (Reuters)
Aptar is benefiting from several attractive Pharma growth drivers, including injectables, GLP-1-related elastomeric components, biologics, vaccines, consumer healthcare and prescription nasal-delivery systems. (AptarGroup)
The company retains differentiated technology and financial flexibility: its June 2026 presentation cited more than 7,000 active and pending patents, Pharma representing 69% of 2025 adjusted EBITDA, a robust balance sheet and approximately $1.2 billion returned to shareholders over five years. (AptarGroup)
Adjusted EPS fell 12% year over year in the first half of 2026 to $2.61, while second-quarter adjusted EPS declined to $1.42 from $1.68, indicating earnings pressure despite reported revenue growth. (AptarGroup)
Second-quarter adjusted EBITDA margin fell to 20.7% from 22.6%, with margin declines in Pharma, Beauty and Closures caused by unfavorable mix, lower volumes, resin pass-through timing and production-line ramp-up costs. (AptarGroup)
Underlying growth remains modest: first-half core sales increased only 1%, with Pharma core sales flat, while currency effects and acquisitions reduced reported growth; emergency-medicine destocking remains a near-term Pharma headwind. (AptarGroup)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Aptargroup Financial Performance
Revenues and expenses
Aptargroup Earnings Performance
Company profitability
Upcoming events
No upcoming events
Aptargroup News
AllArticlesVideos
Funds containing Aptargroup
AllEURGBPUSD
Fund name | Fund size | $ATR weighting |
|---|---|---|
SPDR S&P US Dividend Aristocrats€SPYD | €3.3B | 0.33% |
SPDR S&P US Dividend Aristocrats£USDV | £2.8B | 0.33% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.23% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.23% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.